Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron to acquire Amgen IL-1 patents

Executive Summary

Amgen consent agreement with FTC would require Amgen to license certain patent rights to Regeneron, the only company besides Amgen and Immunex to have an IL-1 inhibitor in clinical trials. Amgen would also have to license certain TNF inhibitor patent rights to Serono. Immunex markets the TNF product Enbrel (etanercept) for arthritis, and Abbott and Pharmacia have TNF products in development...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS040163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel